CSV meets cyber‑readiness

Drugmakers are treating cyber recovery as a validation problem, not just a security problem, because a breached system can stop a compliant production line cold. (securityboulevard.com) Computer system validation is the documented proof that software and connected equipment do what they are supposed to do, consistently, for their intended use. In pharmaceutical plants, that can include manufacturing execution systems, laboratory information management systems, enterprise resource planning software, and plant-floor control systems. (colortokens.com) The Food and Drug Administration said in final guidance published September 24, 2025 that it recommends a risk-based “computer software assurance” approach for production and quality-system software, updating older validation practices rather than discarding them. The International Society for Pharmaceutical Engineering’s GAMP 5 second edition, released July 29, 2022, likewise emphasizes risk-based decisions and “critical thinking” for compliant computerized systems. (federalregister.gov) (ispe.org) The convergence with cybersecurity starts with a simple fact: if ransomware, a wiper, or unauthorized changes alter a validated system, a manufacturer may no longer be able to trust the records that prove what was made, when, and under what controls. United States rules in 21 CFR Part 11 say electronic records and signatures must be trustworthy and reliable, and European Union Good Manufacturing Practice Annex 11 sets specific requirements for computerized systems. (colortokens.com) (ecfr.gov) (gmp-compliance.org) That changes the recovery playbook. Restoring a server from backup is not enough if a company cannot show which configurations were approved, which interfaces fed critical data, and whether the restored state still matches the validated one. (securityboulevard.com) The article’s practical advice is to map dependencies before an incident: which systems feed batch records, which quality systems sign off releases, which controllers run the line, and which configurations are recoverable. It also argues that companies need validation packages and test approaches that still work during disaster recovery, not only during planned upgrades. (securityboulevard.com) Manufacturing security guidance from the National Institute of Standards and Technology points in the same direction. NIST Special Publication 1800-10 says industrial control systems face frequent, sophisticated attacks and recommends risk assessment, change control, file-integrity checking, allowlisting, and authentication to protect operations and system integrity. (csrc.nist.gov) In a pharmaceutical plant, those controls have a second job: they help preserve the evidence needed to show a system remained in control or was restored to a known-good state. That is why cyber teams, quality teams, and validation teams are increasingly working from the same asset lists, configuration baselines, and recovery runbooks. (securityboulevard.com) (csrc.nist.gov) The thread running through the new guidance and the breach-readiness pitch is narrow but concrete: a drugmaker that cannot re-establish trust in its computerized systems cannot quickly restart regulated production. (federalregister.gov) (securityboulevard.com)